Please login to the form below
Lamzede
This page shows the latest Lamzede news and features for those working in and with pharma, biotech and healthcare.
Chiesi launches new rare disease R&D division
Chiesi already markets rare disease therapy Lamzede (velmanase alfa), which is approved by the European Medicines Agency for the treatment of patients with mild to moderate alpha-mannosidosis. ... Chiesi acquired Lamzede when it bought Zymenex in 2013
Latest news
-
Daily Brief: Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more
England’s cost effectiveness watchdog NICE has published draft guidance not recommending Chiesi’s enzyme replacement therapy Lamzede (velmanase alfa).
-
Chiesi's ultra-rare genetic disorder therapy wins European backing
Chiesi Group’s Lamzede (velmanase alfa) has been recommended for approval in Europe, putting it on course to become the first pharmacological therapy to reach the market for Alpha-Mannosidosis (AM). ... Lamzede, which was acquired when the Italian
-
NICE backs Europe's first stem cell therapy
be joined by Lamazym/Lamzede (velmanase alfa), used as an enzyme replacement therapy for the genetic disorder alpha-mannosidosis which is currently under review in Europe.
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- A creative awakening – how pharma is bringing innovation to the patient journey
- Our Top 5 Pharma Picks From Cannes Lions
- Live Webinar: Streamlining the Drug Development Process to Transform Global Health
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- How pharma found its voice – health communications for a brave new world
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- Pfizer, Mylan move ahead with generics merger and spin-out
- Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease
- Roche shares new positive Ocrevus data for MS patients
PMHub
Collected Group
Collected Group is a forward thinking healthcare communication company that supports biopharma and diagnostic companies to engage in more lasting...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
